Islet cell transplantation

The discovery of insulin changed the course of history in the treatment of diabetes. However, despite tremendous progress in insulin formulations and treatment strategies, insulin treatment still cannot fully prevent chronic complications and intensive insulin treatment to improve metabolic control,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	CAMILLO RICORDI
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2004
Materias:	трансплантация островков сахарный диабет бета-клетки поджелудочной железы Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/7988befa8b8349119391dcf757cb7ee2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7988befa8b8349119391dcf757cb7ee2
record_format	dspace
spelling	oai:doaj.org-article:7988befa8b8349119391dcf757cb7ee22021-11-14T09:00:09ZIslet cell transplantation2072-03512072-037810.14341/2072-0351-5603https://doaj.org/article/7988befa8b8349119391dcf757cb7ee22004-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5603https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The discovery of insulin changed the course of history in the treatment of diabetes. However, despite tremendous progress in insulin formulations and treatment strategies, insulin treatment still cannot fully prevent chronic complications and intensive insulin treatment to improve metabolic control, has often paralleled an increased risk of severe hypoglycemia. A cure for Type 1 diabetes should include: ? Restoration of self tolerance, to prevent recurrence of autoimmunity ? Restoration of physiologic metabolism by replacement of the biologic function (insulin producing cells) that was partially of completely impaired as a result of the disease process. ? Prevention of destruction of the new insulin producing cells by the recipient immune system in the absence of any treatment that could introduce an additional risk to the patient, which could be comparable to, or higher than the risk imposed by disease progression under exogenous insulin treatment. Pancreatic islets could be considered an ideal and more physiologic alternative to insulin, as they can restore metabolic control after transplantation, preventing the development of chronic complications. In fact, islets are capable of perfectly timed insulin release and can keep glucose levels in the normal range, functioning for an entire lifetime, if they are not destroyed by the recipient's immune system. Significant progress has been recently reported in the translational research approach towards the development of a cure for Type 1 diabetes. There is now strong evidence for the technical feasibility of human islet isolation and purification procedures. Proof of function of isolated human islets has been clearly established both in animal models and in pilot clinical trials of human islet allotransplantation in patients with surgical and Type 1 diabetes. Additional research in now needed to improve the current clinical results in terms of long term prevention of rejection and recurrence of autoimmunity, the development of safe, non diabetogenic immunomodulation strategies and ultimately the achievement of donor specific immune tolerance. If success will be achieved in these areas, then we will face the critical challenge of identifying sufficient and suitable sources of insulin producing tissue to treat the increasing number of patients who could benefit from this form of therapy and which would not be limited to Type 1 diabetes. That is why the work on xenogeneic islets, embryonic and adult stem cells, islet regeneration and proliferation, as well as engineering of insulin producing cells must be continued, to identify the most ideal source of insulin producing tissue that could be utilized on a large scale once the impediments and limitations of immunosuppression will be resolved.CAMILLO RICORDIEndocrinology Research Centrearticleтрансплантация островковсахарный диабетбета-клетки поджелудочной железыNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 7, Iss 2, Pp 14-19 (2004)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	трансплантация островков сахарный диабет бета-клетки поджелудочной железы Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	трансплантация островков сахарный диабет бета-клетки поджелудочной железы Nutritional diseases. Deficiency diseases RC620-627 CAMILLO RICORDI Islet cell transplantation
description	The discovery of insulin changed the course of history in the treatment of diabetes. However, despite tremendous progress in insulin formulations and treatment strategies, insulin treatment still cannot fully prevent chronic complications and intensive insulin treatment to improve metabolic control, has often paralleled an increased risk of severe hypoglycemia. A cure for Type 1 diabetes should include: ? Restoration of self tolerance, to prevent recurrence of autoimmunity ? Restoration of physiologic metabolism by replacement of the biologic function (insulin producing cells) that was partially of completely impaired as a result of the disease process. ? Prevention of destruction of the new insulin producing cells by the recipient immune system in the absence of any treatment that could introduce an additional risk to the patient, which could be comparable to, or higher than the risk imposed by disease progression under exogenous insulin treatment. Pancreatic islets could be considered an ideal and more physiologic alternative to insulin, as they can restore metabolic control after transplantation, preventing the development of chronic complications. In fact, islets are capable of perfectly timed insulin release and can keep glucose levels in the normal range, functioning for an entire lifetime, if they are not destroyed by the recipient's immune system. Significant progress has been recently reported in the translational research approach towards the development of a cure for Type 1 diabetes. There is now strong evidence for the technical feasibility of human islet isolation and purification procedures. Proof of function of isolated human islets has been clearly established both in animal models and in pilot clinical trials of human islet allotransplantation in patients with surgical and Type 1 diabetes. Additional research in now needed to improve the current clinical results in terms of long term prevention of rejection and recurrence of autoimmunity, the development of safe, non diabetogenic immunomodulation strategies and ultimately the achievement of donor specific immune tolerance. If success will be achieved in these areas, then we will face the critical challenge of identifying sufficient and suitable sources of insulin producing tissue to treat the increasing number of patients who could benefit from this form of therapy and which would not be limited to Type 1 diabetes. That is why the work on xenogeneic islets, embryonic and adult stem cells, islet regeneration and proliferation, as well as engineering of insulin producing cells must be continued, to identify the most ideal source of insulin producing tissue that could be utilized on a large scale once the impediments and limitations of immunosuppression will be resolved.
format	article
author	CAMILLO RICORDI
author_facet	CAMILLO RICORDI
author_sort	CAMILLO RICORDI
title	Islet cell transplantation
title_short	Islet cell transplantation
title_full	Islet cell transplantation
title_fullStr	Islet cell transplantation
title_full_unstemmed	Islet cell transplantation
title_sort	islet cell transplantation
publisher	Endocrinology Research Centre
publishDate	2004
url	https://doaj.org/article/7988befa8b8349119391dcf757cb7ee2
work_keys_str_mv	AT camilloricordi isletcelltransplantation
_version_	1718429723068989440

Islet cell transplantation

Ejemplares similares